Company Profile

Industry Sector: Biomedical instrumentation

Company Overview: GeneFluidics is committed to improving the quality of human life with advanced engineering technologies. GeneFluidics was incorporated in 2000 to develop a fast, accurate, and simple testing system for improving worldwide health. By integrating novel bionano and microfluidic technologies, the company’s revolutionary platform enables complex tests that are normally performed only by skilled technicians in a laboratory to be performed by anyone, anywhere.

Target Market(s): Human diagnostics, life science research and pharmaceutical industries.

Key Value Drivers

Technology*: GeneFluidics’ sensor technology enables quantification of nucleic acids and proteins in unprocessed samples on a single platform. Our patented sensor fabrication and electrochemical detection methods provide high sensitivity even in unamplified, unpurified biological samples. Results are delivered within 1 hour.

Competitive Advantage:
- **Multiplexed** - A combination of immunoassays and genetic assays can be performed simultaneously on a sensor array.
- **Fully automated** - Benchtop and portable systems are available which fully automate the assay process.
- **Ultra-sensitive** - Sub-femtomolar (genetic material) and sub-pg/mL (protein) sensitivities are made possible by taking advantage of high turnover enzyme cycling

Plan & Strategy:
GeneFluidics has formed a strategic alliance with BioCheck, Inc., a manufacturer of immunodiagnostics. Visit our assays page for a list of assay kits compatible with GeneFluidics’ sensor technology.
http://www.genefluidics.com/technology#assays

Product Pipeline

Helios is the first affordable multi-channel electrochemical workstation. 16 independent assays can be performed on each sensor chip with Proteus or Helios.

The Proteus Robotic System is designed to automate procedures that typically require extensive labor by skilled technicians.

Management

Leadership: Dr. Vincent Gau – Co-founder, and President. Dr. Gau is a recognized international expert on bioMEMS, nanotechnology and microfluidics.

Scientific Advisory Board:

Dr. Chih-Ming Ho – Chairman of the Board

At UCLA, Dr. Ho currently holds the Ben Rich-Lockheed Martin Professor Chair in the School of Engineering, serves as the Associate Vice Chancellor of Research, and heads the Institute for Cell Mimetic Space Exploration (CMISE) as Director. He is world-renowned for his work in MEMS and microfluidics and is a member or Fellow of numerous honorary societies, including the National Academy of Engineering, the American Physical Society, the American Institute of Aeronautics and Astronautics.